CLINICAL_TRIALS
trial_result
· 2011-11-29
Clinical Trial Update: HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab [Phase 2]
Summary
Phase 2 clinical trial update showing results for HuMax-CD20 (ofatumumab) in patients with chronic lymphocytic leukemia who failed fludarabine and alemtuzumab; …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Leukaemia, Lymphocytic, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2011-11-29